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Congenital cytomegalovirus (CMV) infections represent one leading cause of
neurodevelopmental disorders. Recently, we reported on a rat model of CMV infection
of the developing brain in utero, characterized by early and prominent infection
and alteration of microglia—the brain-resident mononuclear phagocytes. Besides their
canonical function against pathogens, microglia are also pivotal to brain development.
Here we show that CMV infection of the rat fetal brain recapitulated key postnatal
phenotypes of human congenital CMV including increased mortality, sensorimotor
impairment reminiscent of cerebral palsy, hearing defects, and epileptic seizures. The
possible influence of early microglia alteration on those phenotypes was then questioned
by pharmacological targeting of microglia during pregnancy. One single administration
of clodronate liposomes in the embryonic brains at the time of CMV injection to
deplete microglia, and maternal feeding with doxycyxline throughout pregnancy to
modify microglia in the litters’ brains, were both associated with dramatic improvements
of survival, body weight gain, sensorimotor development and with decreased risk of
epileptic seizures. Improvement of microglia activation status did not persist postnatally
after doxycycline discontinuation; also, active brain infection remained unchanged by
doxycycline. Altogether our data indicate that early microglia alteration, rather than
brain CMV load per se, is instrumental in influencing survival and the neurological
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outcomes of CMV-infected rats, and suggest that microglia might participate in the
neurological outcome of congenital CMV in humans. Furthermore this study represents
a first proof-of-principle for the design of microglia-targeted preventive strategies in the
context of congenital CMV infection of the brain.
Keywords: cytomegalovirus, microglia, rat model, fetal brain, neurological outcome
INTRODUCTION
Perinatal and congenital infections cause morbidity and
mortality throughout the world. Some pathogens are of
considerable public health impact, such as Toxoplasma gondii,
rubella, human immunodeficiency virus, Zika virus, and human
cytomegalovirus (CMV). CMVs belong to the Herpesviridae
family. In humans, congenital CMV infection can cause severe
neurological diseases and defects (Adler and Nigro, 2013). These
include microcephaly, polymicrogyria, hearing loss, cerebral
palsy, epileptic seizures and intellectual disability, as well as
the as-yet elusive influence on the emergence of schizophrenia,
autism or epilepsy. Despite the incidence and the medical and
socioeconomical burden of congenital CMV, which represents
about 1% of all live births, the pathophysiological mechanisms
underlying the emergence of neurodevelopmental disorders
remain elusive (Cheeran et al., 2009). In the absence of effective
preventive or curative therapies, understanding the pathogenesis
is mandatory before strategies for early interventions can be
designed and tested. The pathophysiology of congenital CMV
disease is inherently complicated and involves different stages,
from maternal CMV primary infection or reactivation and
the associated maternal immune responses, to infection and
dissemination within the developing brain—not to mention the
crossing of the placental and blood-brain barriers.
Insights into the early events following CMV infection
of the developing brain are particularly needed. CMVs are
generally species-specific; thus, the development of relevant
animal models has been, and will continue to be, critical to our
understanding of the mechanisms involved in CMV congenital
brain disease (Britt et al., 2013; Cekinovic et al., 2014). Whereas
multiple routes (intracranial, intraperitoneal or intraplacental)
and developmental timepoints (antenatal or neonatal) of CMV
inoculation were used, and despite the lack of materno-fetal
transmission of CMV infection in rodents, convergent insights
into the alteration of innate and adaptive immune responses
have emerged from such models (Kosmac et al., 2013; Sakao-
Suzuki et al., 2014; Bradford et al., 2015; Slavuljica et al., 2015;
Cloarec et al., 2016; Seleme et al., 2017). The production of
cytokines by glial cells, the recruitment of peripheral immune
cells, and the altered status of microglia, are all likely to
influence neuropathogenesis. Microglia are targeted by CMV
during human congenital disease (Teissier et al., 2014) and in
murine models of intraplacental or neonatal infections (Kosugi
et al., 2002; Sakao-Suzuki et al., 2014). Recently, we reported on a
rat model of CMV infection of the developing brain displaying
prominent infection of brain myelomonocytic cells and early
alteration of microglia (Cloarec et al., 2016). Microglial cells
originate from erythromyeloid progenitors located in the yolk sac
during embryogenesis (Ginhoux et al., 2010) and represent the
resident mononuclear phagocytes of the brain (Ginhoux et al.,
2013; Ginhoux and Jung, 2014). These cells play crucial roles not
only in immune defense, maintenance of the neural environment,
injury, and repair, but also in neurogenesis, synaptogenesis,
synaptic pruning, connectivity, and modulation of synaptic and
neuronal activity (Frost and Schafer, 2016). Importantly, early
microglial responses might well combat against CMV infection;
but these responses might likely have detrimental effects by
interacting with important neurodevelopmental processes.
To which extent and to which direction—favorable or
detrimental—early microglia alteration would influence the
emergence and severity of neurodevelopmental phenotypes in
the developing brain in utero in the context of CMV infection
represent an important pathophysiological question. Herein, we
have tested whether early pharmacological targeting of microglia
during pregnancy impacts postnatal neurological manifestations
in our previously reported rat model of CMV infection of the
embryonic brain (Cloarec et al., 2016) and have identified a
critical role for microglia.
MATERIALS AND METHODS
Experimental Design
In this study, we explored whether neuroimmune events
associated with brain CMV infection in utero could be involved
in the emergence of postnatal neurological consequences. We
first explored whether infected rats would display phenotypes
related to the human pathology. We then tested two independent
methods in order to target microglia: (1) doxycycline treatment,
which is known to attenuate microglia activation in the
developing brain (Cunningham et al., 2013) and (2) liposomes
containing clodronate to deplete microglia by uptake and release
into the cytosol of a non-hydrolysable ATP analog leading to cell
death. Finally, we determined whether animals would still display
postnatal neurological consequences following each treatment.
Ethical Statement
Animal experimentations were performed in accordance with
the French legislation and in compliance with the European
Communities Council Directives (2010/63/UE). Depending on
the age of the animals, euthanasia were performed after
anesthesia with 4% isoflurane with overdose of pentobarbital
(120mg/kg) or with decapitation. This study was approved under
the French department of agriculture and the local veterinary
authorities by the Animal Experimentation Ethics Committee
(Comité d’Ethique en Expérimentation Animale) n◦14 under
licenses n◦01010.02 and n◦2016100715494790.
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CMV Infection and Pharmacological
Treatments
Wistar rats (Janvier Labs, France) were raised and mated at
INMEDPost Genomic Platform (PPGI) animal facility. Rat CMV
recombinant Maastricht strain (RCMV-1145-147-gfp) with a
green fluorescent protein (GFP) expression cassette, and its
production, purification and titration, were reported previously
(Baca Jones et al., 2009). In utero intracerebroventricular (icv)
injections were performed at embryonic day 15 (E15) as
previously described (Salmi et al., 2013; Cloarec et al., 2016)
in embryos from timed pregnant rats that were anaesthetized
with ketamine (100 mg/kg)/xylazine (10 mg/kg). Microglia were
depleted in vivo with clodronate liposomes icv (0.5 µL/injection,
Encapsula Nanosciences) co-injected with 1.75 103 pfu of rat
CMV; alternatively, phosphate-buffered saline (PBS)-containing
liposomes (0.5 µL/injection) were co-injected as a control
(untreated condition). Microglia status was modified in the
embryos in vivo with doxycycline per os given to the mother
throughout pregnancy (200 mg/kg in food pellet chow, Safe).
Immunohistochemistry Experiments
Immunohistochemistry experiments on coronal brain sections
(50–100µm, vibratome, Microm; 14µm, cryostat, Leica) were
carried out as described previously (Cloarec et al., 2016) with
the following primary (anti-Iba1: 1/500, Wako; anti-Cd68,
Ed1 clone: 1/200, Millipore) and secondary (Alexa Fluor 568
or 647-conjugated goat anti-rabbit or anti-mouse IgGs; Life
Technologies) antibodies. Hoescht 33258 (1:2000, Sigma) was
used for nuclei staining.
For tissue clearing experiments (see next subsection), whole
infected brains were first immunostained as follows. Tissue
samples were dehydrated in methanol/1X PBS series: 20, 40, 60,
80, 100 × 2 for 1h each at room temperature (RT) and then
incubated overnight at RT on a platform shaker in a solution
of PBSG-T [PBS 1X containing 0.2% gelatin (Sigma-Aldrich),
0.5% Triton X-100 (Sigma-Aldrich) and 0.02% Sodium-Azide
(Sigma-Aldrich)]. Next, samples were transferred to PBSG-T
containing anti-GFP antibodies (AVES, 1:2,000) and placed at
37◦C, with rotation at 100 rpm, for 10 days. This was followed by
six washes of 1 h in PBSG-T at RT. Samples were then incubated
in secondary antibodies (Donkey anti-chicken Alexa-Fluor 647,
Jackson ImmunoResearch, 1:500) diluted in PBSG-T for 2 days
at 37◦C. After six washes of 1 h in PBSG-T at RT, samples were
stored at 4◦C in PBS until clearing.
Tissue Clearing
Tissue clearing was performed according to previously reported
3DISCO and iDISCO+ clearing procedures (Erturk et al.,
2012; Belle et al., 2014, 2017; Renier et al., 2014) with slight
modifications. Briefly, all incubation steps were performed at RT
in a fume hood using a 15ml centrifuge tube (TPP, Dutscher).
Samples were first dehydrated in a graded series (20, 40, 60,
80, and 100%) of methanol (Sigma-Aldrich) for 1 h. This was
followed by a delipidation step of 20min in dichloromethane
(DCM; Sigma-Aldrich). Samples were transferred to 100% DCM
and finally cleared overnight at RT in dibenzylether (DBE; Sigma-
Aldrich).
Quantitative Reverse Transcription
Polymerase Chain Reaction (qRT-PCR)
Total RNA samples were extracted from whole CMV-infected
brains at P1 using TRIZOL reagent (Life Technology). cDNAwas
synthesized from 1 µg of total RNA using Quantitect Reverse
Transcription Kit according to manufacturer protocol (Qiagen).
RT-PCRs were carried out using SYBR-Green chemistry (Roche
Diagnostics) and Roche amplification technology (Light Cycler






control gene Rpl19 (ribosomal protein L19) (Cloarec et al., 2016).
Primer pairs were optimized to ensure specific amplification
of the PCR product and the absence of any primer dimer.
Quantitative PCR standard curves were set up for all analyses.
Microscopy, Cell Counting, and Image
Analyses
Images of brain sections were acquired with a Stereo Microscope
Olympus SZX16 equipped with digital camera DP73, or a
Zeiss Axio Imager Z2 microscope with structured illumination
(ApoTome) equipped with Zeiss AxioCam MRm camera and
processed using Axiovision software, or with a confocal laser
scanning microscope Leica TCS SP5X equipped with a white
light laser, a 405 nm diode for ultra-violet excitation, and 2
HyD detectors. For cell counting analyses on immunostained
brain sections, at least three adjacent brain sections were
analyzed throughout the entire z-dimension for each sample
using confocal microscopy, according to previously reported
procedures (Cloarec et al., 2016) and as further detailed in
Supplementary Materials. A phagocytic activation index (PAI)
was defined as the ratio of Iba1+ Ed1+ cells to the total number
of Iba1+ cells. ImageJ software was used to quantify fluorescence
areas on coronal brain sections selected according to their
coordinates, as indicated in the rat brain atlas (Khazipov et al.,
2015), excluding the meninges. Percentage of fluorescence area
of a given brain section was obtained by normalizing to the total
area of this brain section.
Whole-brain imaging after tissue clearing was performed
using ImspectorPro software (LaVision BioTec) with a binocular
stereomicroscope (MXV10, Olympus) equipped with a 2X
objective (MVPLAPO, Olympus) used at magnifications 0.8X.
A laser (NKT Photonics SuperK extrem) with a 640/30 nm
emision filtre and two cylindrical lenses was used to generate
a light sheet. Samples were placed in an imaging chamber
made of 100% quartz (LaVision BioTec) filled with DBE and
illuminated from the side by the laser. Images were acquired
with an Andor NEO sCMOS camera (2,560 × 2,160 pixel size,
LaVision BioTec). The Z-step size between each image was fixed
at 3µm. 3D (three-dimensional)-images, quantifications and
movies were generated using Imaris x64 software (version 8.4.1,
Bitplane). Stack images were first converted to Imaris file (.ims)
using ImarisFileConverter. 3D reconstruction of the sample was
performed using “volume rendering.” Brain segmentation was
performed using “surface” tool by creating a mask around each
volume to remove meninges and peripheral tissue containing
antibody aggregates, allowing GFP intensity quantification only
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in brain parenchyma. GFP mean intensity obtained was then
normalized to the total volume of segmented brain. 3D pictures
andmovies were generated using the “snapshot” and “animation”
tools.
Flow Cytometry
Leukocytes from brains obtained from anesthetized P1 or P7
pups were isolated as previously described (Cloarec et al., 2016).
Approximately, 1–3 × 106 leukocytes were incubated with
Zombie NIR Fixable Viability kit (1:200; Biolegend) for 20min
at RT. Fc receptors were blocked using mouse anti-rat CD32
antibody (FcγII receptor, clone D34-485) for 10min. at 4◦C to
reduce nonspecific binding. Blocked cell samples were stained
with antibodies against combinations of cell surface markers as
previously described (Cloarec et al., 2016). An average of 1.3 ×
105 living singlet cells were analyzed per brain equivalent on a
BD LSRFortessa cell cytometer and raw data were analyzed using
FACSDiva V8.0 software (BD Biosciences).
Phenotyping
Acquisition of classical developmental righting and cliff aversion
reflexes was monitored daily between postnatal day 1 (P1)
and P20 as further detailed in Supplementary Materials. The
presence of hindlimb paralysis was determined visually in
animals that had a postural misplacement and immobility of their
hindlimbs. Generalized tonic-clonic epileptic seizures (GTCS)
were detected visually, usually after animal handling, especially
during cage changing and behavioral testing. They consisted in
a classical behavioral sequence including (i) movement arrest
and loss of postural equilibrium (ii) hypertonic posture of
the trunk, limbs and tail, symmetrically, and (iii) repeated,
large clonic movements of all limbs, often with respiratory
arrest, incontinence, motor automatisms such as chewing
and grooming, terminated by a catatonic phase. Auditory
experiments were performed and monitored as detailed in
Supplementary Figure 1.
Data Analysis and Statistics
Data were expressed as means ± s.e.m. unless otherwise stated.
Non-parametric Mann Whitney test (two-tailed) followed by
Bonferroni correction, if needed, and non-parametric Kruskall-
Wallis test were used to detect heterogeneous distribution
between groups followed by Dunn’s post-hoc test for multiple
comparisons. Univariate Cox analysis and Fisher’s exact test
(two-tailed) were used to compare between survival distributions
and rates. Parametric Student’s t-test was used to compare
between body weight gains, whereas Chi-square test with
Bonferroni correction and mixed model for repeated data were
used for all other phenotypic comparisons between groups
of animals. Generalized mixed models allow incorporating
correlations while observations are collected over time. The
group of animal was entered as a covariate and the time point
(time whenmeasures were repeated) was introduced as a random
effect with autogressive covariance structure to account for the
within-subjects correlations, assuming that two measurements
timely close to each other are closely correlated, and less
correlated when they get farther apart. As we are modeling
binary data, we specified the binomial distribution and the logit
function as the link one using the PROC GLIMMIX with sas 9.4.
Significance threshold was set at 0.05 unless otherwise stated in
the figure legends.
RESULTS
CMV Infection of the Rat Fetal Brain Leads
to Postnatal Mortality and to Neurological
Manifestations
To determine whether CMV infection and the accompanying
immune responses in the developing rat brain could be
associated with the emergence of postnatal consequences,
recalling those seen in the corresponding human congenital
disorder, recombinant rat CMV expressing GFP was injected
icv in embryos from timed-pregnant rats at E15 as previously
described (Cloarec et al., 2016).
During the period of evaluation, i.e., until P20, CMV infection
significantly decreased postnatal survival as compared with
control animals, which were injected icv with the vehicle (MEM)
(p = 0.0017) (Figures 1A, 2; Supplementary Table 1). Indeed,
70.4% (38 out of 54 pups) of CMV-infected newborns died in
the first three postnatal weeks, compared to 2.9% (one out of 34)
controls (p < 10−4, Chi2 test). In contrast, antenatal mortality
was not affected as no significant difference was observed in the
ratio of live animals at birth (72.8%, n = 103) as compared to
controls (68.5%, n = 54) (Fisher’s exact test, two-tailed). Body
weight was similar at P1 between CMV-infected (7.20 g ± 0.10)
and control (7.40 g± 0.11) newborns (Student’s t-test), but CMV
infection in utero significantly impacted the postnatal evolution
of body weight gain (p < 10−4) (Figure 1B; Supplementary
Table 1).
Congenital CMV infection is the leading cause of non-
hereditary congenital sensorineural hearing loss (Smith et al.,
2005). In order to assess whether CMV infection in utero
causes hearing loss in rats, auditory tests were performed at
P40. Hearing thresholds were significantly higher for clicks (p
= 0.0146) and for 24 kHz bursts (p = 0.0017) in the CMV
infected group compared to the control group (Supplementary
Figure 1; Supplementary Table 1). As hearing loss caused by
congenital CMV infection may be progressive in children, we
aimed at evaluating hearing thresholds in CMV-infected animals
at later ages. However, a significant deterioration of hearing
thresholds was also detected in control (MEM-injected) rats
between P40 and P60 (data not shown); this restrained us from
performing such a longitudinal analysis in CMV-infected rats as
the deterioration of hearing thresholds seen in control rats would
likely preclude reliable interpretation of the overall data.
Human congenital CMV infection is also well known to be
a contributing cause of cerebral palsy, a group of disorders
involving variable degree of sensorimotor disabilities (Colver
et al., 2014). Sensorimotor development was evaluated by daily
monitoring pups between P1 and P20 for the acquisition of the
classic righting and cliff aversion reflexes (Rousset et al., 2013).
The righting reflex consisted in assessing the ability of rodent
pups to coordinate the necessary movement to roll over from
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FIGURE 1 | CMV infection of the embryonic rat brain causes decreased survival and neurodevelopmental defects that can be prevented in utero by microglia-targeted
drug-based strategies. Phenotypic investigations (see Figure 2) in the three first postnatal weeks in pups previously subjected to the following procedures during
pregnancy: vehicle intraventricularly (icv) (MEM; n = 34, four litters); CMV icv, pregnant rat fed with doxycycline (DOX) during pregnancy (CMV+DOX; n = 36, four
litters); CMV icv, untreated pregnant rat (CMV; n = 54, six litters); CMV with clodronate liposomes icv (CMV+LipoCLO; n = 23, two litters); CMV with PBS liposomes
icv (CMV+LipoPBS; n = 33, four litters). Sex ratio did not differ between the five groups at birth (p = 0.15, Chi-square test). (A) Kaplan-Meier survival curves indicated
significant decreased survival in the CMV vs. MEM group, and significant rescues in the CMV+DOX and CMV+LipoCLO groups vs. their untreated counterparts (CMV
and CMV+LipoPBS, respectively). (B) Cumulative body weight decreased significantly in the CMV vs. MEM group. Significant improvements were seen in the
CMV+DOX and CMV+LipoCLO groups vs. their untreated counterparts (CMV and CMV+LipoPBS, respectively). (C,D) The proportion of animals succeeding to the
righting reflex (C) or the cliff aversion reflex (D) sensorimotor tests decreased significantly in the CMV vs. MEM group, and significantly improved in the CMV+DOX vs.
CMV group, and in the CMV+LipoCLO vs. CMV+LipoPBS group. (E,F) Hindlimb paralysis (E) and generalized tonic-clonic epileptic seizures (GTCS) (F) occurred
significantly more frequently in the CMV vs. MEM group. This improved significantly in the CMV+DOX vs. untreated CMV group and in the CMV+LipoCLO vs.
untreated CMV+LipoPBS group. Note that because the most severely affected pups were at higher risk to death, a misleading effect of apparent improvement with
time could be perceived from curve shapes even for untreated conditions. Left sides of the cohorts legend: univariate Cox analysis (A), mixed model for repeated data
(B–D), or Chi2 test with Bonferroni correction (E,F). Right sides of the cohorts legend: odds ratio (OR) ± confidence intervals correspond to the risks in the untreated
vs. their corresponding treated groups: postnatal mortality (A); failure at test (C,D); hindlimb paralysis (E); GTCS (F). ***p < 0.001; **p < 0.01; *p < 0.05; ns, not
significant, for all figure panels, except (E,F) where ***p < 0.0002; **p < 0.002. NA, not available.
their backs onto their paws. A significant proportion of CMV-
infected pups showed inability to right, as compared with MEM-
injected pups, which all performed the test successfully (p <
10−4; Figures 1C, 2; Supplementary Figure 2A; Supplementary
Table 1). In the cliff aversion test, pups were placed with their
forepaws overhanging the edge of a board and the time required
to turn away from the edge was recorded. Control MEM-injected
rats showed a clear performance improvement from P4 as all
succeeded the test after P8 (Figures 1D, 2; Supplementary Table
1). In contrast, a significant proportion of CMV-infected pups
was unable to complete the cliff aversion test all along the first
three postnatal weeks (p < 10−4; Figure 1D, 2; Supplementary
Figure 2B; Supplementary Table 1). Hindlimb paralysis was
detected in the first three postnatal weeks in 83.3% of CMV-
infected pups, likely preventing animals from turning away from
the cliff. Hindlimb paralysis was not seen in any non-infected pup
(p< 10−4; Figures 1E, 2; Supplementary Table 1).
Patients with human congenital CMV are also at high risk
of postnatal epileptic seizures (Suzuki et al., 2008). Consistently,
24.1% of CMV-infected rat pups exhibited GTCS at least once
in the first three postnatal weeks whereas none of MEM-
injected pups ever showed any GTCS (p = 0.002; Figure 1F, 2;
Supplementary Table 1). Interestingly, a clear relationship
between epileptic seizures and death was observed wherein 85%
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FIGURE 2 | Overview of day-per-day phenotype assessment in the first three postnatal weeks. Color-encoded overview of postnatal test evaluations and observations
performed as from postnatal day P1 (see also Figure 1; Supplementary Table 1). Five experimental cohorts of rats were analyzed postnatally: i/control embryos were
injected intraventricularly (icv) with vehicle at E15 (MEM; n = 34 from four litters); ii/embryos were injected icv with rat CMV at E15 and were born from dams fed with
(Continued)
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FIGURE 2 | control chow all over pregnancy (CMV; n = 54 from six litters); iii/embryos were injected icv with rat CMV at E15 and were born from dams fed with
doxycycline-supplemented chow all over pregnancy (CMV+DOX; n = 36 from four litters); iv/embryos were injected icv with rat CMV and with control (PBS) liposomes
at E15 (CMV+LipoPBS; n = 33 from 4 litters); v/embryos were injected icv with rat CMV and with clodronate liposomes at E15 (CMV+LipoCLO; n = 23 from 2 litters).
The table shows color-encoded results for each individual pup evaluated on a daily basis (P1 to P20 columns) for the phenotypic parameters as detailed below.
Performances at the righting (R sub-column) and cliff aversion (C sub-column) reflexes were measured from P1 or from P4, respectively; performances to right (R) or
to turn away from the cliff (C) were color-encoded following a binary rule (blue: success; red: failure). For righting reflex evaluation, rat pups were placed in a supine
position, and the time required to flip to the prone position was measured. For the cliff aversion reflex, animals were placed with their forepaws overhanging the edge
of a board; the time required to turn >90◦ away from the edge was recorded. For both tests, a maximum observation time of 30 s. was used. Each pup was also
monitored daily for the appearance of hindlimb paralysis (H sub-column) and of generalized tonic-clonic seizures (GTCS) (S sub-column); the data were color-encoded
following a binary rule where blue reflected the absence of either event, whereas red indicated the occurrence of paralysis or seizure. When pups died, this was also
annotated on the table and color-encoded in dark gray. Hatched cells: data unavailable.
of seizing rats deceased, as compared to 37% of non-seizing
rats (p < 10−4, Chi2 test). Similarly, 72% of rats with hindlimb
paralysis deceased during the period of evaluation, as compared
to 13% of non-paralyzed rats (p< 10−4).
Acute icv Injection of Clodronate
Liposomes in Utero Depletes Microglia and
Improves the Postnatal Outcome
The consequences of rat CMV infection as described above,
recapitulated several cardinal clinical features of the human
pathology. The early and prominent infection and alteration
of microglia upon CMV infection of the developing rat brain
in utero (Cloarec et al., 2016) suggested that microglia might
contribute to the pathophysiology of congenital CMV. In order
to evaluate the possible impact of microglia on the emergence of
the neurological and other developmental defects, experiments
were designed to target microglia with drugs during pregnancy.
In a first series of experiments, microglia were acutely depleted
with clodronate liposomes co-injected icv together with rat
CMV at E15. Immunohistochemistry experiments confirmed
that clodronate liposomes triggered a significant decrease in
the total number of Iba1+ microglial cells in the dorsolateral
part of the striatal wall of the lateral ventricles taken as the
region of interest (ROI) at P1 (112.3 cells/ROI ± 9.37), as
compared to the condition where PBS liposomes were used
(558.5 cells/ROI ± 128.3; p = 0.0022; Figure 3A; Supplementary
Table 2). A significant decrease in the absolute number of
phagocytically active, Iba1+ Ed1(CD68)+ microglia was also
oberved (clodronate liposomes: 27.17 cells/ROI ± 2.80; PBS
liposomes: 141 cells/ROI ± 23.82) (p = 0.0022). This was
associated with a dramatic reduction of CMV spreading, since
GFP+ infected cells were barely visible within the brains of
treated embryos. The reduction in CMV infection was confirmed
by quantifying the percentage of fluorescent areas in coronal
brain sections taken from treated and untreated pups at P1 (p =
0.0022; Figure 3B; Supplementary Table 3).
Microglia depletion and reduction of brain CMV infection
were associated with a significant improvement of survival
and neurodevelopmental outcomes. Postnatal mortality was
reduced by 2.9 fold (p = 0.012) in clodronate-treated, CMV-
infected pups, relative to untreated, infected pups (Figures 1A, 2;
Supplementary Table 1). Indeed, 69.6% (16 out of 23 newborns)
of clodronate-treated, CMV-infected newborns survived at P16,
as compared to 12.1% (4 out of 33) of untreated, CMV-infected
newborns (p < 10−4, Chi2 test). A similar significant increase in
body weight gain was observed in the clodronate-treated pups (p
< 10−4; Figure 1B; Supplementary Table 1).
CMV-infected pups treated with clodronate liposomes
in utero also performed significantly better at the righting
and the cliff aversion reflexes when compared to infected
pups, which had received control (PBS) liposomes in utero
(Figures 1C,D, 2; Supplementary Figure 2; Supplementary
Table 1). With clodronate the odds in favor of success to righting
and to cliff aversion tests were at 20.1:1 and 18.4:1, respectively (p
< 10−4 for both). Hindlimb paralysis also improved significantly
(p < 10−4) with clodronate liposomes (17% of rat pups)
as compared with control liposomes (88%) (Figures 1E, 2;
Supplementary Table 1). There was a dramatic, 120.4-fold
decrease in the risk to hindlimb paralysis in clodronate-treated
CMV-infected rats (p < 10−4). Epileptic seizures also occurred
less frequently in the first three weeks of life upon treatment
with clodronate liposomes (8.7% of rats experiencing at least
one seizure), as compared to PBS liposomes (24.2% of epileptic
rats) but this difference did not reach statistical significance (p =
0.14) (Figures 1F, 2; Supplementary Table 1). However, when the
risk of seizures was considered, it decreased significantly by 8.1-
fold in clodronate-treated, CMV-infected rats when compared to
their PBS-liposomes counterparts (p< 10−4).
Hence a single injection of clodronate liposomes at the time of
CMV icv infection not only led to depletion of microglia and to a
dramatic reduction of active CMV infection in the rat developing
brain, but the treatment also led to a stunning improvement
of survival, body weight gain, sensorimotor development and
epileptic seizures in early postnatal life.
Chronic Administration of Doxycycline to
Pregnant Mothers Improves Microglia
Phenotype
Tetracyclines can efficiently modify microglia status in the
brains of rat pups after chronic maternal administration
during pregnancy (Cunningham et al., 2013). Tetracyclines
impact on microglia phenotype independently of their canonical
antibacterial action (Tikka et al., 2001). In order to confirm
the possible role of microglia in the emergence of phenotypes
associated with brain CMV infection, doxycycline, a second-
generation, lipophilic tetracycline that crosses blood-brain and
placental barriers, was administered per os to pregnant dams
from E0 to birth. The effects of doxycycline treatment on
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FIGURE 3 | Clodronate liposomes deplete microglia and reduce CMV spreading in the developing brain. Recombinant rat CMV allowing expression of GFP (green) in
the infected cells was injected icv in rat embryos at E15 together with either clodronate liposomes (LipoCLO) to deplete microglia, or PBS liposomes (LipoPBS) as
control. (A) LipoCLO decreased the number of Iba1+ microglia (red) and of Iba1+, Ed1+ (cyan) phagocytically active microglia. Three to four adjacent coronal brain
sections were analyzed by confocal microscopy throughout the entire z-dimension (n = 6 brains in each condition). ROI: region of interest (775 × 775 µm2 ). Bar:
100µm. Mann-Whitney test, two-tailed, with Bonferroni correction. **p < 0.005. (B) LipoCLO reduced rat CMV infection of the brain. Brains were analyzed at P1
using fluorescent binocular microscopy. Three sections were selected according to their coordinates in the rostrocaudal axis (left). CMV infection decreased
dramatically after treatment with LipoCLO (n = 6 brains in each condition), as quantified by measuring the proportion of fluorescent (GFP) areas. Bar: 1mm.
Mann-Whitney test, two-tailed. **p < 0.01.
microglia phenotype was tested by immunohistochemistry in
the dorsolateral part of the striatal wall of the lateral ventricles,
a region where active CMV infection was frequently detected
(Cloarec et al., 2016), and by multicolor flow cytometry analysis
of the whole brain.
In line with previously reported experiments (Cloarec et al.,
2016), rat CMV infection at E15 led to a significant increase
in the proportion of phagocytically active, Iba1+ Ed1(CD68)+
microglia/macrophages cells at P1. Indeed, the phagocytic
activation index (PAI), defined as the ratio of Iba1+ Ed1+
cells to the total number of Iba1+ cells, was significantly
increased (42.74% ± 6.16) as compared with control (MEM-
injected) rats (PAI = 14.28% ± 4.29) (p = 0.0174), and
was significantly improved by doxycycline (17.32% ± 6.44;
p = 0.0321) (Figure 4A; Supplementary Table 2). Consistent
data were obtained when whole brains were analyzed at
P1 by flow cytometry (Figure 4B; Supplementary Table 4).
As previously reported (Cloarec et al., 2016), a significant
increase in the proportion of major histocompatibility (MHC)
class II-positive microglia (fraction IV: CD45low/int, CD11b/c+,
RT1B+) was detected in CMV-infected brains (13.98% ±
2.12) as compared with controls (0.73% ± 0.05; p <
0.0001). This increase in activated microglia was significantly
counteracted in doxycycline-treated, CMV-infected pups (5.66%
± 1.13) (p = 0.0483). The proportions of other types of
CD45+ hematopoietic cells were not changed by doxycycline
(Figure 4B; Supplementary Figure 3; Supplementary Table 4).
Importantly, the favorable impact of the doxycycline in utero
treatment on reactive microglia seen at P1 did not last
after treatment discontinuation. The proportion of reactive,
CD45low/int, CD11b/c+, RT1B+ microglia (fraction IV) at P7
were similar in treated (55.76%± 4.60) and in untreated (58.93%
± 5.54) CMV-infected rats (Figure 4C; Supplementary Figure 3;
Supplementary Table 4).
The consequences of in utero treatment with doxycycline on
brain CMV infection per se were also evaluated. Independent
series of brains were submitted to tissue clearing using the
iDisco method (Renier et al., 2014). Fluorescence-based 3D
quantification of the infected areas of whole brains showed
no difference between treated and untreated rats at P1
(Figure 5A; Supplementary Table 3; Supplementary Videos 1, 2).
Consistently, no significant difference in GFP gene expression
was found by qRT-PCR between treated and untreated CMV-
infected brains at P1 (Figure 5B; Supplementary Table 5).
Moreover, the proportions of CMV-infected, GFP+ cells as
detected by flow cytometry analysis performed on CD45+
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FIGURE 4 | CMV infection of the embryonic rat brain leads to altered microglia phenotype, which is rescued by maternal feeding with doxycycline throughout
pregnancy. (A) Microglia status in the lateral ventricles was assessed on coronal sections observed by confocal microscopy at P1 by quantifying microglial cells (red,
Iba1+) and phagocytically active microglial cells (Iba1+, red; Cd68/Ed1+, cyan). Those values were then used to calculate the phagocytic activation index (PAI)
defined as the ratio of the number of Iba1+, Ed1+ activated cells to the total number of Iba1+ cells. PAI increased in the CMV vs. the MEM group. Doxycycline
(CMV+DOX) significantly counteracted PAI increase (n = 6 brains in each condition). ROI: region of interest (387 × 200 µm2 ). Bar: 50µm. Kruskall-Wallis test followed
by Dunn’s post-hoc test. *p < 0.05. (B,C) Flow cytometry analysis of leukocytes collected at P1 (B) and P7 (C). Total leukocytes (CD45 events) were gated for CD45
and Cd11b/c, thus defining fractions I (lymphocytic cells), II (myelo-monocytic cells) and III (resident microglial cells) (see also Supplementary Figure 3). Fraction III
corresponding to CD45low/int, CD11b/c+ microglial cells was further characterized for RT1B expression to identify reactive microglia (RT1B+; fraction IV).
Representative flow cytometry plots and the corresponding quantifications are shown for each group. (B) At P1, the increased proportion of reactive microglia
triggered by CMV infection was significantly counteracted by doxycycline (n = 6 MEM; n = 11 CMV; n = 12 CMV+DOX). (C) At P7, i.e., 7 days after discontinuation of
doxycycline, the decreased proportion of total microglial cells (fraction III) and, within that fraction, the increased proportion of reactive microglia (fraction IV) triggered
by CMV infection, were not counteracted by doxycycline treatment given in utero (n = 6 MEM; n = 12 CMV; n = 12 CMV+DOX). Kruskall Wallis test followed by
Dunn’s post test. ***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant.
hematopoietic cells isolated from CMV-infected brains at P1,
were not significantly different between doxycycline-treated and
untreated pups (Figure 5C; Supplementary Table 4). Also, no
significant difference in GFP+ infected cells was found by flow
cytometry at P7 between doxycycline-treated and untreated pups.
Hence the early and transient impact of doxycycline on microglia
phenotype was not accompanied by a parallel decrease in CMV
infection of the brain.
Chronic Doxycycline Administration to the
Mother Throughout Pregnancy Improves
the Postnatal Outcome
Owing to the transient improvement of microglia status upon
maternal administration of doxycycline during pregnancy, we
then tested whether this would in turn impact the postnatal
outcomes. In doxycycline-treated, CMV-infected pups, survival
rate improved significantly as compared to infected pups from
untreated dams (Figure 1A, 2; Supplementary Table 1). CMV-
infected pups treated with doxycycline in utero had a risk 5.1
lower to postnatal death in the first three postnatal weeks, than
their untreated, CMV-infected counterparts (p = 0.0006). At
P20, 86.1% (n = 31 out of 36 newborns) of infected pups from
doxycycline-treated dams had survived as compared to 29.6% (n
= 16 out of 54 newborns) of infected pups from untreated dams
(p < 0.001, Chi2 test). Significant improvement in body weight
gain was also observed in CMV-infected pups after doxycycline
treatment in utero (p< 10−4; Figure 1B; Supplementary Table 1).
Whereas no rescue could be obtained at P40 on hearing
threshold after doxycycline treatment (Supplementary Figure 1;
Supplementary Table 1), responses to sensorimotor tests
(righting and cliff aversion reflexes) improved significantly
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FIGURE 5 | Maternal feeding with doxycycline throughout pregnancy does not impact rat CMV infection of the brain. Green fluorescent protein (GFP) expression was
used to monitor infection of the pups’ brains by rat CMV with three independent methods. (A) Tissue clearing. Whole brains from P1 rat pups were submitted to tissue
clearing and GFP expression was quantified by measuring mean fluoresence intensity normalized to each corresponding total brain volume. Representative examples
of clarified brains are shown (light sheet microscopy) (see also Supplementary Videos 1, 2). No significant difference was found between the CMV+DOX group (n = 7)
and its untreated counterpart (CMV; n = 9). Bar: 2mm. Mann Whitney test, two-tailed. ns, not significant. (B) qRT-PCR. Relative mRNA expression of GFP was
assessed by quantitative RT-PCR in CMV-infected brains at P1, using RPL-19 as reference gene. No difference was found between the CMV+DOX group (n = 14)
and its untreated counterpart (CMV; n = 18). Values of fold change represent averages from triplicate measurements for each sample. Mann Whitney test, two-tailed.
ns: not significant. (C) Flow cytometry. Relative proportion of GFP+, CMV-infected cells was estimated by flow cytometry analysis of CD45+ cells isolated from
CMV-infected brains at P1 and at P7. No difference was found between the CMV+DOX group (n = 12) and its untreated counterpart (CMV; n = 11). SSC,
side-scattered light. Mann Whitney test, two-tailed. Ns, not significant.
(p = 0.025 and p < 10−4, respectively) in infected pups treated
with doxycycline in utero (success to righting: odds ratio 2.6:1;
success to cliff aversion: odds ratio 9.9:1) (Figures 1C,D, 2;
Supplementary Figure 2; Supplementary Table 1).
Hindlimb paralysis was also observed less frequently after
doxycycline administration (Figures 1E, 2; Supplementary
Table 1). Hence, 50% (n = 18 out of 36) of doxycycline-treated,
CMV-infected pups displayed paralysis during the first three
postnatal weeks, as compared to 83.3% (n = 45 out of 54) in
the untreated counterparts (p = 0.001). Consistently, the risk
of hindlimb paralysis reduced by 6.2 fold (p = 0.03). Whereas
the proportion of epileptic, CMV-infected rats decreased, albeit
not significantly (p = 0.12), upon treatment with doxycycline
(11%) as compared with untreated, infected rats (24%), the risk
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of epileptic seizures during the period of evaluation decreased
significantly by 5.9-fold in CMV-infected rats receiving
doxycycline in utero (p < 10−4; Figures 1F, 2; Supplementary
Table 1).
Hence, while doxycycline administration during pregnancy
did not significantly modify the amount of active CMV infection
in the developing brain after birth, it led to a transient
modification of microglia phenotype that was associated with
long-term favorable effects on survival, body weight gain and
neurodevelopmental outcomes.
DISCUSSION
Phenotypes in the Rat and in Humans
Studies on different rodent models that showed similarities
with the human disease at the neuroanatomical, cellular and
molecular levels, have suggested that neuroimmune alterations
might play an important pathophysiological role. In a rat
model of CMV infection of the developing brain in utero, we
reported recently the detection of early neuroimmune anomalies
including microglia alteration (Cloarec et al., 2016). Utilizing
this model, we herein demonstrate altered postnatal oucomes in
CMV infected neonates including increased postnatal lethality,
decreased body weight gain, early-onset epileptic seizures,
sensorimotor impairment reminiscent of cerebral palsy, and
hearing defects. Despite the fact that maternal, placental and
peripheral embryonic events were purposedly bypassed by
directly infecting the embryonic brain in utero, this model
recapitulated several fundamental phenotypic features of the
human pathology following CMV infection. Moreover, the
postnatal outcomes varied dramatically among the rat pups, as
in the human disease. This indicates that in addition to the
aforementioned upstream factors, the somehow unpredictable
and highly diverse outcome of congenital CMV infection
might rely, at least partly, on fetal brain-related events.
The consequences of CMV infections of the brain on the
future neurological phenotypes had been hardly addressed in
rodent models until recently. Auditory features associated with
inflammation of the inner ear recalling the hearing losses seen in
human congenital infections were recently reported in a neonatal
mouse model (Bradford et al., 2015). Also, early and long-term
neurological dysfunctions including acquisition of the righting
and cliff aversion reflexes as well as motor performances and
social behavior have been reported very recently in a murine
model of neonatal infection (Ornaghi et al., 2017). Interestingly,
in the present rat model of rat CMV infection in utero, more
dramatic neurological consequences were observed, probably
because CMV was inoculated directly into the ventricles and at
an earlier developmental stage.
Targeting Microglia With Doxycycline and
Clodronate
Generally, microglia-targeted rescue strategies had already been
successfully used in a range of models for various postnatal
neurological insults and disorders, such as neonatal excitotoxic
brain damage (Dommergues et al., 2003), experimental
autoimmune encephalitis (Ponomarev et al., 2011), cerebral
palsy (Kannan et al., 2012), or Alzheimer disease (Hong et al.,
2016). In the present model of prenatal cerebral infection, two
previously reported microglia-targeted drug-based strategies
both led to the successful rescue of the neurological phenotypes.
While the respective modes of action of clodronate liposomes on
the one hand, and doxycycline on the other hand, are unrelated at
themolecular and subcellular levels, we cannot firmly exclude the
possibility that they would both have influenced the phenotypes
by microglia-independent, off-target mechanisms. Doxycycline
might have other biological consequences (Yrjanheikki et al.,
1999) such as a broader anti-inflammatory action on other
immune and non-immune cells (Yrjanheikki et al., 1998).
Hence, it was shown in a murine model of multiple sclerosis
that minocycline, another second-generation tetracycline, can
decrease leukocytes infiltration into the spinal cord (Brundula
et al., 2002). However, in our model doxycycline did not modify
the different fractions corresponding to the non-microglial
immune cells detected in the CMV-infected brains (e.g.,
monocytes/macrophages, dendritic cells, T cells and B cells),
as analyzed by flow cytometry (see Supplementary Figure 3).
Moreover tetracyclines have already been used to decrease
microglia activation in NMDA-induced excitotoxicity (Tikka
et al., 2001), experimental autoimmune encephalitis (Popovic
et al., 2002), or epileptogenesis (Abraham et al., 2012).
Influence of Early Microglia Alteration on
the Postnatal Phenotypes
Whereas clodronate liposomes led to microglia depletion
associated with a dramatic decrease in brain CMV infection,
doxycycline promoted microglia modification while leaving
CMV infection of the brain unchanged. Moreover, the early
improvement of microglia was associated with long-term
beneficial effects. Indeed, the effect of doxycycline on microglia
was transient and was no longer detected at P7. Despite this
observation, the favorable impact on the clinical phenotypes
lasted long after treatment was stopped. This suggests that the
early alteration of microglia following CMV infection had long-
term detrimental effects on the neurological and other outcome.
Although we cannot exclude the existence of more subtle changes
such as a modification in the distribution of CMV in different
brain areas, our data indicate that early microglia alteration,
rather than CMV infection and viral cytopathic effects per
se, promoted the emergence of most neurological and other
postnatal manifestations. The relationship between CMV load
and the occurrence and severity of CMV-related phenotypes has
indeed been challenged in a murine model of neonatal CMV
infection (Kosmac et al., 2013; Seleme et al., 2017) and in human
congenital CMV (Revello et al., 1999; Boppana et al., 2013).
Our data are congruent with recent reports on inflammatory
processes in CMV infection of the murine neonatal brain
(Kosmac et al., 2013; Bradford et al., 2015; Kawasaki et al., 2015;
Slavuljica et al., 2015; Seleme et al., 2017).
The microglia-targeted strategies used in the present study led
to significant improvements of sensorimotor impairments and of
epilepsy. The alteration and possible role of microglia in epileptic
disorders and in cerebral palsy have already been discussed
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(Fleiss and Gressens, 2012; Vezzani et al., 2012; Devinsky et al.,
2013). The presence of hearing impairment in the present model
might be difficult to interpret. First, a progressive deterioration
of auditory performances was seen in the control rats; this is
consistent with previous reports on the existence of age-related
hearing loss in control Wistar rats (Alvarado et al., 2014), which
was likely related with the lack of strial melanin in albino rodents
(Ohlemiller, 2009). Second, a detrimental effect of doxycycline
on the development of the auditory system cannot be excluded,
notably given its known potential auditory toxicity. Third,
whereas hearing loss caused by murine neonatal CMV infection
was recently associated with persistent inflammation of the inner
ear (Bradford et al., 2015), the lack of significant improvement
after doxycycline treatment in uteromight indicate that microglia
does not play an important role in hearing impairment in our
model.
Microglia in Brain Development and in
Neurodevelopmental Disorders
A crucial pathogenic impact of early microglia alteration in
the context of congenital CMV is consistent with the role of
microglia in the development, the functioning and the pathology
of the central nervous system (Prinz and Priller, 2014). Microglia
undergo several programmed changes during brain development
in rodents (Matcovitch-Natan et al., 2016), impact synaptic
transmission, as well as synapse formation and elimination.
Microglia also shape embryonic and postnatal brain circuits
(Paolicelli et al., 2011; Schafer et al., 2012). The alteration of
microglia by CMV infection early during brain development
might well have disrupted the timing of such developmental
programs, leading to altered development of neuronal networks
and the subsequent detrimental neurological outcome. As an
example, susceptibility to epileptic seizures could be caused by
several microglia-dependent processes, such as the alteration of
migration and neocortical laminar distribution of interneurons,
the altered control of synaptic development and regulation, or
an increased glutamate release (Paolicelli and Ferretti, 2017).
As a matter of fact, the transient improvement of microglia
status as obtained here with doxycycline was sufficient to obtain
dramatic improvements of the neurological phenotypes. Prenatal
alteration of microglia and the accompanying microglia priming
can have long-term consequences on synaptic functioning
(Roumier et al., 2008) and could participate in the susceptibility
to neurodevelopmental disorders occurring as consequences of
viral infections of the developing brain.
Besides Microglia
Whereas early microglia improvement was sufficient to impact
significantly the prenatal phenotypes, this of course does not
exclude the important roles likely played in parallel by other
components of the neuroimmune system, either at the molecular
level such as cytokines and chemokines, or at the cellular
level such as infiltrating monocytes or lymphocytes. Hence, the
role of T lymphocytes infiltration in CMV infection has been
proposed (Bantug et al., 2008); T cells control viral spread
within the brain and are pivotal in resolving acute CMV
infection of the neonatal murine brain (Slavuljica et al., 2015).
However, the amount of T cells was not impacted by doxycycline
in the present model, which is consistent with the lack of
any significant change in CMV infection observed here after
doxycycline treatment. Similarly, doxycycline did not modify the
proportions of dendritic cells or monocytes within the infected
brains. Other types of glial cells such as astrocytes are also likely
to play a pathophysiological role, as reported in other models of
CMV infection (Lokensgard et al., 2016; Ornaghi et al., 2017),
and notably given the known reciprocal interactions between
microglia and astrocytes.
Besides CMV
Apart from congenital CMV, microglia infection and alteration
can occur in a wide range of viral encephalitis. Microglia
might participate in neuronal damage seen in encephalitis
caused by Japanese encephalitis virus (Thongtan et al., 2012).
Microglia status might inform on neuronal dysfunctioning
following murine leukemia virus-induced encephalopathy (Xue
et al., 2010). Microglia might also participate in HIV-associated
cognitive and behavioral impairments (Hong and Banks, 2015).
Il34−/− mice with fewer microglia were protected from synaptic
defects triggered byWest Nile virus infection (Vasek et al., 2016).
Interestingly also, acute administration of minocycline prevented
against long-term behavioral outcome in a model of temporal
lobe epilepsy caused by infection with Theiler’s virus (Barker-
Haliski et al., 2016). Whether microglia-targeted strategies could
be successfully applied to these and other congenital infections of
the brain remains to be demonstrated.
From the Rat Model to the Human Disease
Although extrapolation to the corresponding human pathology
should be approached with caution, it is tempting to speculate
that microglia might also play an important role in human
neurological disease following congenital CMV infection. As a
matter of fact, microglial nodules and infected microglial cells
were detected in human CMV-infected fetal brains (Teissier
et al., 2014). While different innovative strategies to combat
against CMV infection and its consequences have been proposed
recently in complementary rodent models (see Ornaghi et al.,
2017), microglia represent another promising target for various
neuropathological conditions (Cartier et al., 2014) Strategies
directed toward the immune system have already been proposed
with the use of corticosteroids in a mouse model of neonatal
CMV infection (Kosmac et al., 2013) and with the administration
of immunoglobulins to prevent against human CMV congenital
infection (Revello et al., 2014). Pharmacological interventions
in utero have already been successful in rodent models of
motor impairment (Yamada et al., 2009) and of epilepsy (Salmi
et al., 2013). The use of doxycycline in pregnancy could also be
revisited in line with its potential benefits (Cross et al., 2016).
Generally risk reduction of fetal infection and subsequent disease
still remains a crucial issue (Hamilton et al., 2014). Together
with progress in fetal medicine (Bianchi, 2012) and in the
identification of reliable biomarkers to predict severity (Desveaux
et al., 2016), the present study, which now warrants confirmation
and expansion using complementary rodent models of CMV
infection and other microglia modifying tools, represents a first
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proof-of-principle for the future design of microglia-targeted
strategies to prevent against the severe neurological outcome of
congenital CMV infection of the brain.
CONCLUDING REMARKS
In conclusion, we have shown here that the neurological and
other phenotypes caused by CMV infection of the rat brain
in utero, are caused by the early activation of microglia, rather
than by the virus load by itself, at least in this model - suggesting
that microglia might also influence the corresponding human
disease.
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